Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Tax Provisions (2023 - 2025)

Lyra Therapeutics has reported Tax Provisions over the past 3 years, most recently at $2000.0 for Q4 2025.

  • Quarterly results put Tax Provisions at $2000.0 for Q4 2025, down 66.67% from a year ago — trailing twelve months through Dec 2025 was $11000.0 (down 71.79% YoY), and the annual figure for FY2025 was $11000.0, down 71.79%.
  • Tax Provisions for Q4 2025 was $2000.0 at Lyra Therapeutics, down from $3000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for LYRA hit a ceiling of $17000.0 in Q4 2023 and a floor of $2000.0 in Q2 2025.
  • Median Tax Provisions over the past 3 years was $9500.0 (2023), compared with a mean of $9083.3.
  • Biggest five-year swings in Tax Provisions: changed 0.0% in 2024 and later plummeted 83.33% in 2025.
  • Lyra Therapeutics' Tax Provisions stood at $17000.0 in 2023, then tumbled by 64.71% to $6000.0 in 2024, then crashed by 66.67% to $2000.0 in 2025.
  • The last three reported values for Tax Provisions were $2000.0 (Q4 2025), $3000.0 (Q3 2025), and $2000.0 (Q2 2025) per Business Quant data.